ACM
CNSP icon

ADAR1 Capital Management’s CNS Pharmaceuticals CNSP Stock Holding History

ADAR1 Capital Management’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Buy
+70,000
New +$294K 0.02% 231

Other funds holding CNSP

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

ADAR1 Capital Management's CNSP Position: Q2 2026 in Review

ADAR1 Capital Management opened a new position in CNS Pharmaceuticals (CNSP) in Q2 2026: 70,000 shares worth $335K. The stake represents 0.02% of the portfolio and ranks #231 among its holdings.

11 funds tracked by Wall St. Rank hold CNSP as of Q2 2026.

  • ADAR1 Capital Management held 70,000 shares of CNS Pharmaceuticals worth $335K as of Q2 2026.
  • CNS Pharmaceuticals was a new ADAR1 Capital Management position in Q2 2026.
  • CNS Pharmaceuticals made up 0.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #231 holding.
  • 11 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.